Martin S. Rhee

Clinical targeting of HIV capsid protein with a long-acting small molecule

John O. Link, Martin S. Rhee, Winston C. Tse et al. · Nature · 2020 · 392 citations · Full text

Natural Sciences, Human Retrovirus, Immunology +10

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

Peter Ruane, Edwin DeJesus, Daniel Berger et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2013 · 304 citations

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

Sorana Segal‐Maurer, Edwin DeJesus, Hans‐Jürgen Stellbrink et al. · New England Journal of Medicine · 2022 · 270 citations · Full text

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

Joel E. Gallant, Eric S. Daar, François Raffi et al. · The Lancet HIV · 2016 · 165 citations

Treatment And Prevention, Medicine, Antiviral Drug Development +10

A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection

Andrew Zolopa, Paul E. Sax, Edwin DeJesus et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2013 · 145 citations

Serum Creatinine, Week 96, Treatment And Prevention +14